A randomised study of continuous infusional 5-Fluorouracil (5FU) with or without mitomycin-C in patients with neuroendocrine tumours
Completed
- Conditions
- euroendocrine tumoursCancerMalignant neoplasm of other endocrine glands and related structures
- Registration Number
- ISRCTN53478221
- Lead Sponsor
- The Royal Marsden NHS Foundation Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Histological evidence of neuroendocrine tumours not amenable to surgery or radiotherapy
2. Patients evaluable for response must have bi-dimensionally measurable disease as assessed by chest X-ray or computed tomography (CT) scan
3. This disease must be outside previously irradiated areas
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Response rate<br>2. Toxicity<br>3. Time to disease progression<br>4. Survival<br>5. Quality of life
- Secondary Outcome Measures
Name Time Method o secondary outcome measures
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 5-Fluorouracil's efficacy in neuroendocrine tumours as per ISRCTN53478221?
How does mitomycin-C combination therapy compare to standard-of-care regimens for malignant neuroendocrine tumours?
Which biomarkers correlate with response to continuous 5FU infusion in endocrine gland cancers?
What adverse events are associated with prolonged 5FU administration in ISRCTN53478221 and how are they managed?
Are there alternative chemotherapy combinations to 5FU/mitomycin-C for treating neuroendocrine neoplasms?